<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435458</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8911</org_study_id>
    <nct_id>NCT03435458</nct_id>
  </id_info>
  <brief_title>Balloon to Induce Labor in Generous Women.</brief_title>
  <acronym>BIGW</acronym>
  <official_title>Balloon to Induce Labor in Generous Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rate of obesity increases continuously in France as in many developing countries.The risk
      of cesarean delivery is increased in obese compared to normal-weight women and postpartum
      complications as infections, thromboembolic events and related maternal death, are more
      common among obese women who deliver by cesarean than both normal-weight women with caesarean
      deliveries and obese women with vaginal deliveries. Unfortunately, obesity is associated with
      a higher rate of failed induction requiring a cesarean delivery and especially in
      nulliparous.

      Methods of induction for obese women have to be improved to decrease the c-section rate but
      investigators should also be cautious on the type and dose of PG not to affect the neonatal
      wellbeing associated with uterine hyperstimulation.

      The aim of this study is to demonstrate the efficacy of the association of mechanical and
      pharmacological cervical ripening (balloon catheter plus 50 µg oral prostaglandin E1) versus
      pharmacological cervical ripening alone (50 µg oral prostaglandin E1) to reduce the rate of
      caesarean sections in nulliparous obese women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rate of obesity increases continuously in France as in many developing countries. In
      2012, in the US, one third of all pregnant women were obese. The risk of cesarean delivery is
      increased in obese compared to normal-weight women and postpartum complications as
      infections, thromboembolic events and related maternal death, are more common among obese
      women who deliver by cesarean than both normal-weight women with caesarean deliveries and
      obese women with vaginal deliveries.

      Prevalence of post-term is increased in obese pregnant women and the rate of induction of
      labor is twice the rate of normal-weight women, 42% versus 23% in the 2010 French National
      Survey.

      Unfortunately, obesity is associated with a higher rate of failed induction requiring a
      cesarean delivery and especially in nulliparous.

      Methods of induction for obese women have to be improved to decrease the c-section rate but
      investigators should also be cautious on the type and dose of PG not to affect the neonatal
      wellbeing associated with uterine hyperstimulation.

      In a recent randomized clinical trial (RCT), the rate of c-section after labor induction in
      obese women was not increased in obese women compared to normal-weight women with balloon
      catheter but it was also increased with prostaglandin E2 (PGE2) and moreover with higher rate
      of uterine hyperstimulation. Recently, low dose of oral misoprostol (PGE1) has been showed to
      be the drug with the lowest rate of c-section after induction of labor in all women and
      balloon catheter to be associated with the lowest rate of hyperstimulation. Because safety of
      these two specific methods for induction of labor, a comparison 1 to 1 were done recently for
      induction of labor in singletons with comparable results.

      Very few studies have focused on induction of labor in obese women even if the rate of
      maternal and neonatal complications are higher.

      The efficacy of combining these two methods with different mechanism of induction have been
      showed recently but no study has been published today on obese women. Recently a trial have
      showed a shorter induction-delivery time with the combination (misoprostol-foley) for
      induction of labor in the whole population with less need of oxytocin during labor without
      more complications neither for the mother nor for the baby.

      The aim of this study is to demonstrate the efficacy of the association of mechanical and
      pharmacological cervical ripening (balloon catheter plus 50 µg oral prostaglandin E1) versus
      pharmacological cervical ripening alone (50 µg oral prostaglandin E1) to reduce the rate of
      caesarean sections in nulliparous obese women.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a randomized, multicentre, open-label, controlled trial comparing association of balloon catheter plus oral prostaglandin E1 versus oral prostaglandin E1 alone to induce labor in a 1:1 randomization of nulliparous obese women.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the association of mechanical and low dose oral misoprostol compared to oral misoprostol alone, to reduce the rate of caesarean section of all indications in obese women.</measure>
    <time_frame>Day 0 to day 2</time_frame>
    <description>Assessed by the caesarean section occurrence whatever the indication (binary endpoint).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness criteria.</measure>
    <time_frame>Day 0 to day 2</time_frame>
    <description>Effectiveness criteria chosen for the cost-effectiveness analysis will be the caesarean section rate for all indications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis.</measure>
    <time_frame>Day 0 to day 2</time_frame>
    <description>Cost estimates, for the construction of ICER, will be performed from the health insurance perspective.
Costs taken into account will be those related to the management of obese pregnant women during inpatient stays for the delivery in both arms (i.e. combining method vs. oral prostaglandin alone). They include the costs of initial hospitalization for delivery. The expenses incurred in the management of patients in each arm will be recorded over a the study follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resources consumption collection.</measure>
    <time_frame>Day 0 to day 2</time_frame>
    <description>Resource consumption will be gathered prospectively in each arm, during the follow-up period using a bottom-up approach. Data will be collected from the Medical Information Departments of each center participating in the study for hospitalization costs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs valuation.</measure>
    <time_frame>Day 0 to day 2</time_frame>
    <description>Hospital stays will be valued from the French framework of pricing, the hospital Activity &quot;Tarification à l'activité&quot; (T2A). Hospital stays linked to the patient's care in each strategy will be valued from the French Diagnosis Related Group (DRGs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis.</measure>
    <time_frame>Day 0 to day 2</time_frame>
    <description>A cost-effectiveness analysis will be performed from the health insurance perspective. An Incremental Cost Effectiveness Ratio (ICER) will be calculate to establish a link between costs and medical consequences, expressed in terms of rate of caesarian section rate, between the two strategies for labor induction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">774</enrollment>
  <condition>Maternal Obesity</condition>
  <arm_group>
    <arm_group_label>Balloon catheter + oral misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral misoprostol alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Balloon catheter + oral misoprostol</intervention_name>
    <description>The pharmacological cervical ripening will be administered just after the balloon catheter insertion (after coming back in her room) and will consist of misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.</description>
    <arm_group_label>Balloon catheter + oral misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral misoprostol alone</intervention_name>
    <description>Patients will receive a pharmacological cervical ripening alone that consist of Misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.</description>
    <arm_group_label>Oral misoprostol alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female

          -  pregestational BMI ≥ 30 kg/m2 (weight/height2)

          -  singleton pregnancy with cephalic presentation

          -  nulliparous

          -  ≥ 36 weeks gestational age

          -  decision of induction of labor

          -  bishop score ≤ 5

          -  ≤ 3 uterine contractions / 10 min

          -  ≥ 18 years of age

          -  personally signed and dated informed consent document

          -  ability to comply with the requirement of the study

          -  insurance coverage

        Exclusion Criteria:

          -  deceleration on Fetal Heart Rate (FHR)

          -  placenta praevia

          -  bleeding

          -  premature rupture of membrane

          -  chorioamnionitis

          -  allergy to prostaglandins

          -  contraindication to ballon

          -  active genital herpes infection

          -  HIV infection

          -  fetal estimated weight &gt; 4500g

          -  fetal serious congenital anomaly

          -  patient subject to a legal protection order
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Vayssiere, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Vayssiere, Pr</last_name>
    <phone>5 67 77 13 79</phone>
    <phone_ext>33</phone_ext>
    <email>vayssiere.c@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Guerby, Dr</last_name>
    <email>guerby.p@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne-Rhône-Alpes</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Denis Gallot, Pr</last_name>
      <phone_ext>33</phone_ext>
      <email>dgallot@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Denis Gallot, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <state>Auvergne-Rhône-Alpes</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Céline Chauleur, Pr</last_name>
      <phone>477828611</phone>
      <phone_ext>33</phone_ext>
      <email>celine.chauleur@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Céline Chauleur, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <state>Centre-Val De Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck Perrotin, Pr</last_name>
      <phone>247479280</phone>
      <phone_ext>33</phone_ext>
      <email>franck.perrotin@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Franck Perrotin, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de-France</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Charles Garabadian, Pr</last_name>
      <phone>320446307</phone>
      <phone_ext>33</phone_ext>
      <email>Philippe.deruelle@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Charles Garabadian, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Antoine Beclère</name>
      <address>
        <city>Clamart</city>
        <state>Ile-de-France</state>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandra Benachi, Pr</last_name>
      <phone>145374770</phone>
      <phone_ext>33</phone_ext>
      <email>Alexandra.benachi@abc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandra Benachi, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>Ile-de-France</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Victoire Senat, Pr</last_name>
      <phone>145217717</phone>
      <phone_ext>33</phone_ext>
      <email>Marie-victoire@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Victoire Senat, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier St Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elie Azria, MD</last_name>
      <phone>144127570</phone>
      <phone_ext>33</phone_ext>
      <email>eazria@hpsj.fr</email>
    </contact>
    <investigator>
      <last_name>Elie Azria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Poissy</name>
      <address>
        <city>Poissy</city>
        <state>Ile-de-France</state>
        <zip>78300</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Berveiller, Pr</last_name>
      <phone>139275646</phone>
      <phone_ext>33</phone_ext>
      <email>pberveiller@chi-poissy.st-germain.fr</email>
    </contact>
    <investigator>
      <last_name>Paul Berveiller, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint Denis de la Reunion</name>
      <address>
        <city>Saint-Denis</city>
        <state>La Réunion</state>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thierry Abossolo, MD</last_name>
      <phone>+262262905050</phone>
      <email>thierry.abossolo@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Abossolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St Pierre de la Reunion</name>
      <address>
        <city>Saint-Pierre</city>
        <state>La Réunion</state>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Malik Boukerrou, MD</last_name>
      <phone>+262262359000</phone>
      <email>malik.boukerrou@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Malik Boukerrou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe Vayssiere, Pr</last_name>
      <phone>567771233</phone>
      <phone_ext>33</phone_ext>
      <email>Christophe.vayssiere@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Christophe Vayssiere, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle Plard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Guerby, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>MD</last_name>
      <phone>556795552</phone>
      <phone_ext>33</phone_ext>
      <email>loic.sentilhes@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Loic Sentilhes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <state>Occitanie</state>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent Letouzet, MD</last_name>
      <phone>4 66 68 32 18</phone>
      <phone_ext>33</phone_ext>
      <email>vincent.letouzet@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Letouzet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital St Joseph</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Raoul Desbrière, MD</last_name>
      <phone>491806639</phone>
      <phone_ext>33</phone_ext>
      <email>rdesbriere@hopital-saint-joseph.fr</email>
    </contact>
    <investigator>
      <last_name>Raoul Desbrière, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florent Fuchs, MD</last_name>
      <phone>467336733</phone>
      <phone_ext>+33</phone_ext>
      <email>f-fuchs@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Florent Fuchs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Norbert Winer, Ph</last_name>
      <phone>240083438</phone>
      <phone_ext>+33</phone_ext>
      <email>norbert.winer@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert Winer, Ph</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Fort de France</name>
      <address>
        <city>Fort de France</city>
        <country>Martinique</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Luc Volumenie, Pr</last_name>
    </contact>
    <contact_backup>
      <phone>596 55 20 00</phone>
      <phone_ext>596</phone_ext>
      <email>jean-luc.volumenie@chu-martinique.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Luc Volumenie, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Noumea</name>
      <address>
        <city>Noumea</city>
        <country>New Caledonia</country>
      </address>
    </facility>
    <contact>
      <last_name>Erick Camus, Dr</last_name>
      <phone_ext>33</phone_ext>
      <email>erick.camus@cht.nc</email>
    </contact>
    <investigator>
      <last_name>Erick Camus, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Martinique</country>
    <country>New Caledonia</country>
  </location_countries>
  <reference>
    <citation>Battarbee AN, Palatnik A, Peress DA, Grobman WA. Association of Early Amniotomy After Foley Balloon Catheter Ripening and Duration of Nulliparous Labor Induction. Obstet Gynecol. 2016 Sep;128(3):592-7. doi: 10.1097/AOG.0000000000001563.</citation>
    <PMID>27500341</PMID>
  </reference>
  <reference>
    <citation>Connolly KA, Kohari KS, Rekawek P, Smilen BS, Miller MR, Moshier E, Factor SH, Stone JL, Bianco AT. A randomized trial of Foley balloon induction of labor trial in nulliparas (FIAT-N). Am J Obstet Gynecol. 2016 Sep;215(3):392.e1-6. doi: 10.1016/j.ajog.2016.03.034. Epub 2016 Mar 24.</citation>
    <PMID>27018464</PMID>
  </reference>
  <reference>
    <citation>McMaster K, Sanchez-Ramos L, Kaunitz AM. Evaluation of a Transcervical Foley Catheter as a Source of Infection: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015 Sep;126(3):539-51. doi: 10.1097/AOG.0000000000001002. Review.</citation>
    <PMID>26244535</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Induced labor</keyword>
  <keyword>Maternal obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

